Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05263284
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- guomei
- Target Recruit Count
- 300
- Registration Number
- NCT05262465
- Locations
- 🇨🇳
The fifth medical center of PLA General Hospital, Beijing, Beijing, China
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT05222984
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Kathleen Ludwig
- Registration Number
- NCT05215405
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT05211336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- MEI Pharma, Inc.
- Registration Number
- NCT05209308
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05201066
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Uni of Massachusetts Medical Center, Worcester, Massachusetts, United States
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 650
- Registration Number
- NCT05197192
- Locations
- 🇩🇪
Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
🇩🇪DRK Kliniken Berlin Köpenick, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 85
- Registration Number
- NCT05184842
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.